相关实验视频

Updated: Jul 1, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

目前在非小细胞肺癌中对大脑转移的药理治疗

Takae Okuno¹, Takeshi Isobe¹, Yukari Tsubata²

¹Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, 89-1, Enyacho, Izumo, Shimane, 693-8501, Japan.

Clinical & experimental metastasis

|March 11, 2024

概括

大脑转移在高级非小细胞肺癌中很常见. 本综述探讨了最近的药物治疗方法,包括向药物和免疫检查点抑制剂,用于治疗这些大脑转移.

科学领域:

在瘤学瘤学.
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

大脑转移是晚期非小细胞肺癌 (NSCLC) 的常见和严重并发症.
大脑转移的症状显著损害患者的生活质量,并表明预后不佳.
目前的治疗主要涉及局部手术和放射治疗.

研究的目的:

审查在高级NSCLC中大脑转移的药物治疗中的最新进展.
评估分子向药物和免疫检查点抑制剂的潜在疗效.
讨论最佳的治疗方法,考虑局部与全身治疗.

主要方法:

关于NSCLC大脑转移的药物治疗最近研究的文献综述.
分析临床试验数据和针对性治疗和免疫治疗的研究结果.
综合有关治疗策略及其对预后和生活质量影响的信息.

主要成果:

新出现的证据表明,分子向药物和免疫检查点抑制剂在治疗大脑转移方面表现有前途.
系统疗法可能提供新的选择,可能补充或取代传统的局部治疗.
需要进一步的研究来确定最佳的药物治疗方案和患者选择标准.

结论:

药物治疗,包括向药物和免疫疗法,在管理NSCLC脑转移方面取得了重大进展.
个性化治疗策略对于确定局部和系统方法之间的最佳平衡至关重要.
对新型药物治疗的持续研究对于改善脑转移患者的治疗结果至关重要.

关键词:

大脑转移的转移.免疫检查点抑制剂免疫检查点抑制剂分子向抑制剂分子向抑制剂非小细胞肺癌的非小细胞肺癌.药理疗法药理疗法是一种药理疗法.

更多相关视频

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...